World Copper Stock (OTC:WCUFF), Trade Ideas

World Copper Ltd is a Canadian resource company focused on the exploration and development of its two primary copper porphyry projects, Escalones and Cristal, both located in Chile and it's copper oxide project, Zonia, located in Arizona. World Copper's Chilean assets include five copper porphyry targets, one with estimated resources, significant soluble copper mineralization, and exciting potential to expand the resource base. The Zonia project in Arizona is a project with a clear path to production and compelling economics.

Penny Stocks

ELECF

WCUFF

TSXV:WCU

TSXV:ELEC


  By Steven Ralston, CFA

OTC:WCUFF | TSXV:WCU

READ THE FULL WCUFF RESEARCH REPORT

WCUFF: World Copper Limited Plans Drilling Exploration Programs at Escalones in Chile &amp; Zonia in Arizona in 2nd Half of 2022; Restructuring Zonia Royalties Provides US$2.6 million in Cash. Gross Proceeds of 1st Tranche of Placement Approximately CDN$1.28 million


  By Steven Ralston, CFA

OTCQB:WCUFF | TSXV:WCU 

WCUFF: World Copper Limited Pursuing Exploration &amp; Development of two copper-oxide properties, Escalones Project in Chile and soon-to-be acquired Zonia Project in Arizona

World Copper Ltd

<p>Wedbush  analyst Nick Setyan   maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Neutral and raises the price target from $19 to $20.</p>


News

Price Target

Analyst Ratings

Wedbush Maintains Neutral on Wendy's, Raises Price Target to $20

<p><strong>Super Micro Computer, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares are trading higher Friday as AI and chip stocks gain following<strong> </strong><a href="https://www.benzinga.com/news/earnings/24/04/38444199/microsoft-q3-earnings-revenue-beat-eps-beat-new-era-of-ai-transformation-and-more"><strong>Microsoft Corporation's</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) earnings.</a></p>
<p><strong>The Details:</strong></p>
<p>Microsoft delivered better-than-expected earnings after the bell Thursday. Microsoft CEO <strong>Satya Nadella </strong>highlighted <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38465071/microsoft-q3-shines-light-on-ai-innovation-cycle-analysts-see-plenty-of-runway-for-">strong demand </a>for the company's offerings, particularly in the field of artificial intelligence (AI).</p>
<p>SMCI shares also rose Thursday after <strong>Meta Platforms, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) reported its <a href="https://www.benzinga.com/news/earnings/24/04/38430266/meta-platforms-stock-is-tumbling-thursday-whats-going-on">first-quarter</a> results and increased its capital expenditures outlook amid the company's AI efforts.</p>
<p>SMCI is set to report its third-quarter financial results after the bell on April 30 and will host a conference call to discuss the results at 5:00 p.m. ET the same day. According to estimates from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, analysts expect the company to report earnings of $5.84 per share and quarterly revenue of $3.99 billion.&nbsp;</p>
<p>The company has beat analysts expectations for the last three reported quarters.&nbsp;</p>
<p><em>Related News: </em><a href="https://www.benzinga.com/news/earnings/24/04/38445632/snap-shares-soar-on-better-than-expected-q1-results-daily-active-user-growth-q2-revenue-guidance"><em>Snap Shares Soar On Better-Than-Expected Q1 Results, Daily Active User Growth, Q2 Revenue Guidance</em></a></p>
<h2 class="wp-block-heading"><strong>SMCI Stock Prediction 2024: </strong></h2>
<p>Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.</p>
<p>Shares of Super Micro Computer have an average 1-year price target of $961.13, representing an expected upside of 14.51%.</p>
<p>Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. 1 analyst has a bearish recommendation on Super Micro Computer, while 10 analysts have bullish ratings. The street high price target from Loop Capital is $1500, while the street low from Susquehanna is $250.</p>
<p><strong>SMCI Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Super Micro Computer shares are up 7.46% at $846.17 at the time of publication Friday.</p>
<p><em>Image: Courtesy of Super Micro Computer, Inc. </em></p>


Movers

MSFT

SMCI

What's Going On With Super Micro Computer Stock?

<p>Wedbush  analyst Nick Setyan   maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Neutral and lowers the price target from $95 to $92.</p>


SBUX

Wedbush Maintains Neutral on Starbucks, Lowers Price Target to $92

<p>Evercore ISI Group  analyst Vijay Kumar   maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a In-Line and lowers the price target from $92 to $89.</p>


Evercore ISI Group Maintains In-Line on Edwards Lifesciences, Lowers Price Target to $89

<p>California's solar energy efforts have been so successful that renewable energy has powered 100% of the state's main grid for at least 15 minutes on most days over the past month.</p>
<p>But now, the state and its grid operator are facing an unusual situation. With an abundance of solar energy integrated into the grid, during bright spring days with reduced demand, electricity prices plummet into negative territory. The surplus of solar power results in gigawatts being "curtailed" or effectively wasted, according to a report in The Washington Post.</p>
<p>California's response to balancing renewable energy goals with rooftop solar economics has been to reduce incentives and slow installations. This approach, while addressing short-term grid issues, might hinder long-term solar development in the state. As other states ramp up solar capacity, they could encounter similar challenges in the future.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
<p>States that are starting to experience the same issues include Nevada, which generates 23% of its power from solar, and Hawaii, which has thousands of homes with rooftop solar.</p>
<p>In April 2024, the Biden administration launched a program to create or expand solar programs in low-income and disadvantaged communities.</p>
<p>"Today, my administration is investing $7 billion in a new program called Solar for All that will enable over 900,000 low-income households to have solar on their rooftops for the first time," Biden posted on X on April 22. "Solar for All will give folks more breathing room — and cleaner breathing room at that."</p>
<p><strong>Trending:</strong></p>
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
</ul>
<p>California is one of the states in line to receive a $250 million grant from the Solar for All program to expand residential solar in low-income and disadvantaged communities.</p>
<p>Not everyone shares Biden's enthusiasm for the program. Jessica "Elle" Smith criticized the use of public money for the program, writing, "Translation: ‘I'm blowing $7 billion of your money equipping 900,000 of the most likely to default single-family homes with solar, so when BlackRock sweeps them up in foreclosure, they won't have to do it themselves."</p>
<p>John Podesta, senior adviser to the president for international climate policy, said the program will ensure low-income communities and not just well-off communities will benefit from cost savings that the Solar for All program provides.</p>
<p>"Solar is the cheapest form of electricity — and one of the best ways to lower energy costs for American families," Podesta said at the time the program was announced.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li>Dara Khosrowshahi-Backed Startup Lets You <a href="https://www.benzinga.com/go/dara-backed-startup">Become a Landlord with $100</a>.</li>
<li>Miami Is Expected To Take New York's Place As The US Financial Capital. <a href="https://www.benzinga.com/go/miami-financial-capital">Invest In It With $500 Before That Happens</a>.</li>
</ul>


Real Estate

Shining Too Bright: California's Solar Success Sparks Price Plunge

<p>Wedbush  analyst Nick Setyan   maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Outperform and lowers the price target from $330 to $300.</p>


Wedbush Maintains Outperform on McDonald's, Lowers Price Target to $300

<p>Morgan Stanley  analyst Toni Kaplan   maintains TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) with a Overweight and raises the price target from $87 to $90.</p>


Morgan Stanley Maintains Overweight on TransUnion, Raises Price Target to $90

Asset Sales

Carlyle Group Said To Review Options For Tamko, Including Sale

<p>Wedbush  analyst Nick Setyan   maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Neutral and raises the price target from $45 to $47.</p>


Wedbush Maintains Neutral on Brinker International, Raises Price Target to $47

<p>Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) has been analyzed by 15 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Waste Management, revealing an average target of $213.4, a high estimate of $256.00, and a low estimate of $178.00. Surpassing the previous average price target of $196.20, the current average has increased by 8.77%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714150869_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive Waste Management is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Goldstein</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$214.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Michael Hoffman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$227.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Walter Spracklin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$215.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Walter Spracklin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$211.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Stephanie Moore</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$256.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Bryan Burgmeier</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Stephanie Yee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$197.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Devin Dodge</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$178.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Devin Dodge</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$196.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$212.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Walter Spracklin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$189.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Michael Hoffman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Waste Management. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Waste Management compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Waste Management's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Waste Management's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Waste Management analyst ratings.</strong></a></p>
<h2>About Waste Management</h2>
<p>WM ranks as the largest integrated provider of traditional solid waste services in the United States, operating 259 active landfills and about 337 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.</p>
<h3>Waste Management: A Financial Overview</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Waste Management's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>5.71%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Waste Management's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>9.45%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Waste Management's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>7.12%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Waste Management's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.52%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Waste Management's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.35</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Scoreboard: 15 Ratings For Waste Management

<p>Analysts' ratings for Stericycle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRCL#NASDAQ">SRCL</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $62.17, a high estimate of $75.00, and a low estimate of $48.00. Marking an increase of 11.02%, the current average surpasses the previous average price target of $56.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714150859_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Stericycle by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$69.00</td>
<td>-</td>
</tr>
<tr>
<td>John Mazzoni</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$48.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$69.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Michael Hoffman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$57.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Stericycle. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Stericycle compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Stericycle's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Stericycle's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SRCL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Stericycle analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Stericycle</h2>
<p>Stericycle is the largest provider of medical waste disposal and data destruction (primarily paper shredding) services in the United States. Its next-closest national competitor in medical waste disposal is Sharps Compliance, which generated $76 million of sales in fiscal 2021 before its 2022 acquisition (about 4% of Stericycle's global regulated waste and compliance revenue). Stericycle's data destruction business, Shred-It, is about twice the size of its closest competitor (Iron Mountain's information destruction segment). Stericycle has a global presence, with about 20% of its revenue earned outside North America.</p>
<h3>Stericycle: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Stericycle faced challenges, resulting in a decline of approximately <strong>-2.73%</strong> in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Stericycle's net margin is impressive, surpassing industry averages. With a net margin of <strong>2.29%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Stericycle's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.6%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Stericycle's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.28%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Stericycle's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.71</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SRCL

The Latest Analyst Ratings For Stericycle

Trading Ideas

JEPQ

LDOS

NFLX

CNBC Halftime Report Final Trades: Netflix, Delta Air Lines, Leidos Holdings, JPMorgan Nasdaq Equity Premium Income ETF

<p>In the latest quarter, 13 analysts provided ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $21.15, with a high estimate of $28.00 and a low estimate of $16.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 18.37%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714150846_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of Teladoc Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$17.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Teladoc Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Teladoc Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teladoc Health analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Teladoc Health</h2>
<p>Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.</p>
<h3>Teladoc Health: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Teladoc Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>3.58%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Teladoc Health's net margin is impressive, surpassing industry averages. With a net margin of <strong>-4.37%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Teladoc Health's ROE excels beyond industry benchmarks, reaching <strong>-1.25%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-0.66%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.68</strong>, caution is advised due to increased financial risk.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TDOC

13 Analysts Assess Teladoc Health: What You Need To Know

<p>Across the recent three months, 4 analysts have shared their insights on Oceaneering International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.5, a high estimate of $34.00, and a low estimate of $22.00. Marking an increase of 23.91%, the current average surpasses the previous average price target of $23.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714150838_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Oceaneering International by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>Ian Macpherson</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Oceaneering International. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Oceaneering International compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of Oceaneering International's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OII/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Oceaneering International analyst ratings.</strong></a></p>
<h2>Get to Know Oceaneering International Better</h2>
<p>Oceaneering International Inc is a global provider of engineered services and products robotic solutions to the offshore energy, defense, aerospace, manufacturing and entertainment industries. Most of Oceaneering's products are produced for the offshore oil and gas market. It had a 2020 segment realignment to promote synergies and cost efficiency. The five segments are subsea robotics; manufactured products; offshore projects group; integrity management and digital solutions; and aerospace and defense technologies. Within the segments are two businesses - services and products provided primarily to the oil and gas industry. The firm is also involved in the offshore renewables and mobility solutions industries.</p>
<h3>Breaking Down Oceaneering International's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Oceaneering International's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>22.08%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> Oceaneering International's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>6.8%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Oceaneering International's ROE excels beyond industry benchmarks, reaching <strong>7.46%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Oceaneering International's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.96%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Oceaneering International's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.35</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Oceaneering International: 4 Analysts Share Their Views

<p><strong>Morgan Stanley's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) short percent of float has fallen 7.63% since its last report. The company recently reported that it has <strong>15.13 million shares sold short</strong>, which is 1.21% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.07 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Morgan Stanley Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714150831_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Morgan Stanley has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Morgan Stanley's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Morgan Stanley's peer group average for short interest as a percentage of float is 5.66%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

How Is The Market Feeling About Morgan Stanley?

<p>Cadence Design Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) has outperformed the market over the past 20 years by 8.78% on an annualized basis producing an average annual return of 16.64%. Currently, Cadence Design Sys has a market capitalization of $77.61 billion. </p>
<p><strong>Buying $100 In CDNS:</strong> If an investor had bought $100 of CDNS stock 20 years ago, it would be worth <strong>$2,202.34</strong> today based on a price of $285.20 for CDNS at the time of writing.</p>
<h3>Cadence Design Sys's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714150832_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CDNS

Here's How Much You Would Have Made Owning Cadence Design Sys Stock In The Last 20 Years

<p>9 analysts have expressed a variety of opinions on Cullen/Frost Bankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFR#NYSE">CFR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $120.56, a high estimate of $140.00, and a low estimate of $113.00. Marking an increase of 2.67%, the current average surpasses the previous average price target of $117.43. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714150829_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Cullen/Frost Bankers among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$118.00</td>
<td>-</td>
</tr>
<tr>
<td>Casey Haire</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$121.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$121.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Peter Winter</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$126.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Underperform</td>
<td>$113.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Brody Preston</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$116.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cullen/Frost Bankers. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Cullen/Frost Bankers compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Cullen/Frost Bankers's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Cullen/Frost Bankers's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CFR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Cullen/Frost Bankers analyst ratings.</strong></a></p>
<h2>All You Need to Know About Cullen/Frost Bankers</h2>
<p>Cullen/Frost Bankers is a financial holding company, The company offer commercial and consumer banking services, as well as trust and investment management, insurance, brokerage, mutual funds, leasing, treasury management, capital markets advisory and item processing services across Texas in the Austin, Corpus Christi, Dallas, Fort Worth, Houston, Permian Basin, Rio Grande Valley, and San Antonio regions.</p>
<h3>A Deep Dive into Cullen/Frost Bankers's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Cullen/Frost Bankers faced challenges, resulting in a decline of approximately <strong>-0.44%</strong> in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Cullen/Frost Bankers's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>19.85%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.1%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Cullen/Frost Bankers's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.2%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.06</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 9 Analyst Ratings For Cullen/Frost Bankers

<p><strong>Campbell Soup's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>) short percent of float has risen 16.6% since its last report. The company recently reported that it has <strong>17.18 million shares sold short</strong>, which is 8.99% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 6.87 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Campbell Soup Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714150826_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Campbell Soup has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Campbell Soup's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Campbell Soup's peer group average for short interest as a percentage of float is 3.80%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Peering Into Campbell Soup's Recent Short Interest

<p>Insight Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) has outperformed the market over the past 5 years by 15.04% on an annualized basis producing an average annual return of 26.65%. Currently, Insight Enterprises has a market capitalization of $5.94 billion. </p>
<p><strong>Buying $1000 In NSIT:</strong> If an investor had bought $1000 of NSIT stock 5 years ago, it would be worth <strong>$3,286.36</strong> today based on a price of $182.57 for NSIT at the time of writing.</p>
<h3>Insight Enterprises's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714150826_0_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


NSIT

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,300 Today

<p>4 analysts have expressed a variety of opinions on Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Bristol-Myers Squibb and provided 12-month price targets. The average target is $50.0, accompanied by a high estimate of $54.00 and a low estimate of $43.00. This current average represents a 15.61% decrease from the previous average price target of $59.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714150820_0_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Bristol-Myers Squibb by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Steve Chesney</td>
<td>Redburn Atlantic</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bristol-Myers Squibb. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Bristol-Myers Squibb compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Bristol-Myers Squibb's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bristol-Myers Squibb's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BMY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bristol-Myers Squibb analyst ratings.</strong></a></p>
<h2>Delving into Bristol-Myers Squibb's Background</h2>
<p>Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.</p>
<h3>Financial Insights: Bristol-Myers Squibb</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Bristol-Myers Squibb's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>0.62%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Bristol-Myers Squibb's net margin is impressive, surpassing industry averages. With a net margin of <strong>15.35%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bristol-Myers Squibb's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>6.03%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Bristol-Myers Squibb's ROA excels beyond industry benchmarks, reaching <strong>1.89%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Bristol-Myers Squibb's debt-to-equity ratio is below the industry average. With a ratio of <b>1.41</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
